In summary, Gal-9 can enhance the therapeutic effect of ERCs on attenuation of AIH by reducing the levels of pro-inflammatory cytokines, and enhancing the level of the anti-inflammatory factor. This evidence concerns the gene LGALS9 and autoimmune hepatitis.